7 results
8-K
EX-99.1
GLTO
Galecto Inc
23 Oct 23
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial
9:00am
A of its Phase 1b/2a trial (NCT05240131) (the GALLANT-1 trial) at the European Society of Medical Oncology (ESMO) Congress 2023 in Madrid, Spain
8-K
EX-99.1
hb460k57d52gc
27 Jan 22
Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease
8:31am
- Prev
- 1
- Next